Tekmira Pharmaceuticals (NASDAQ:TKMR)

CAPS Rating: 3 out of 5

Results 1 - 19 of 19

Recs

0
Member Avatar dinasourneil (99.89) Submitted: 11/19/2014 9:56:19 AM : Underperform Start Price: $16.25 TKMR Score: +1.71

again

Recs

0
Member Avatar MMCapitalMgmt (99.82) Submitted: 10/27/2014 5:05:31 PM : Underperform Start Price: $16.59 TKMR Score: +7.38

oops

Recs

0
Member Avatar spgem (< 20) Submitted: 10/27/2014 5:02:49 PM : Underperform Start Price: $18.03 TKMR Score: +15.49

Too volatile - too much Ebola hype - too many players

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 10/10/2014 9:22:20 PM : Outperform Start Price: $24.13 TKMR Score: -41.42

EBOLA! This company is key to the fight against the spread of this deadly disease.

Recs

0
Member Avatar 7527db (24.56) Submitted: 10/10/2014 1:07:13 PM : Outperform Start Price: $23.13 TKMR Score: -37.21

ebola

Recs

1
Member Avatar usubanas (99.67) Submitted: 10/1/2014 3:04:21 PM : Outperform Start Price: $25.30 TKMR Score: -41.65

Joining the ebola ride

Recs

0
Member Avatar EdFromOhio (< 20) Submitted: 10/1/2014 9:22:14 AM : Underperform Start Price: $28.87 TKMR Score: +48.82

Short term pop.

Recs

2
Member Avatar TMFMattyA (99.72) Submitted: 9/24/2014 9:40:46 AM : Underperform Start Price: $24.65 TKMR Score: +38.76

Tekmira's stock has nearly tripled since the start of the Ebola outbreak in West Africa this summer. The company has an experimental drug (in Phase 1 trials) that is designed to treat Ebola -- and various governments have allowed its use in the current epidemic as an emergency solution.

Okay, slightly insensitive thumbing this one down. Ebola is a terrible disease that has claimed the lives of a few thousand people so far this year. But in reality, Ebola is an easily-controlled disease. More people die each year from car accidents than have died from Ebola cumulatively in the last 40 years. So while I hope Tekmira is successful in finding a viable treatment for Ebola, I have a hard time believing it justifies a tripling in the company's stock price.

Recs

1
Member Avatar umight (48.64) Submitted: 9/19/2014 12:51:47 PM : Outperform Start Price: $19.99 TKMR Score: -22.23

Ebola

Recs

1
Member Avatar applecor2 (65.22) Submitted: 9/12/2014 12:36:28 PM : Outperform Start Price: $20.33 TKMR Score: -24.30

By all accounts looks like Dr. Sacra received TKM-Ebola as part of treatment. Pharmaceutical company being asked to remain anonymous on par with TKMR execs methodology. News will break this will pop potential buyout candidate. Speculative play YES but favorable odds here.

Recs

1
Member Avatar jpimp (< 20) Submitted: 8/28/2014 2:07:26 PM : Outperform Start Price: $18.16 TKMR Score: -14.40

Ebola

Recs

1
Member Avatar TerryHoodSr (54.98) Submitted: 6/14/2014 10:04:02 AM : Outperform Start Price: $13.30 TKMR Score: +14.51

TKMR DOWN 10% OVERSOLD?
BUY @ 13 TP 27

Recs

0
Member Avatar portefeuille (99.61) Submitted: 4/22/2014 10:26:54 AM : Outperform Start Price: $19.99 TKMR Score: -29.88

I have 200 TKMR shares in my private (i.e. non-zzporte) portfolio.

Recs

2
Member Avatar kv4507 (< 20) Submitted: 2/24/2014 7:59:52 PM : Outperform Start Price: $23.96 TKMR Score: -44.12

Biotech focused on RNA technology and RNAi therapeutics. Has secured licenses to develop treatment for Alcohol Dependance (AD), an Ebola Vaccine, and various oncology applications. Has agreement with Merck and Alnylam Pharmaceuticals, and in collaboration with US government.

Recs

2
Member Avatar Momentum21 (49.33) Submitted: 2/20/2014 10:19:18 AM : Outperform Start Price: $5.33 TKMR Score: +179.09

Let your winners run...TKMR is a winner.

Recs

2
Member Avatar golfinflyr (< 20) Submitted: 1/21/2014 5:01:35 PM : Outperform Start Price: $12.40 TKMR Score: +17.85

Cheap RNAi platform. Need to leverage their platform out and focus on some bigger targets than Ebola. The stock is very cheap relative to its peers...especially ALNY

Recs

1
Member Avatar phatchips767 (< 20) Submitted: 4/12/2013 5:12:41 PM : Outperform Start Price: $10.55 TKMR Score: +47.96

canadian company that did well for portofeille

Recs

7
Member Avatar rupers (< 20) Submitted: 4/19/2011 7:44:39 AM : Outperform Start Price: $3.07 TKMR Score: +367.98

Tekmira is significantly undervalued, with 3 RNAi products in the clinical pipeline or about to start clinical trials, to include a product aimed at a strain of Zaire ebola under a DOD contract worth up to nearly $170 million. Tekmira's business model is well thought out -- use revenues earned from its RNAi delivery technology to fund its clinical trials and R&D. Tekmira has 5 additional siRNA payload compounds to pick from Alnylam's siRNA technology under very favorable terms. Each of those picks are well worth $5 to 10 million. Tekmira has collaboration or license agreements with some big pharma, to include Merck, Bristol Meyers Squibb, and Takeda. At about $28 million market cap, it's a screaming buy. The only real overhang/cloud is its ongoing litigation with Alnylam, which hopefully will be resolved sooner rather than later -- this will resolve the protection of Tekmira's lipid nanoparticle (LNP) intellectual property.

Recs

8
Member Avatar zzlangerhans (99.81) Submitted: 4/18/2011 12:57:51 PM : Outperform Start Price: $2.78 TKMR Score: +418.06

RNAi is an extremely complex field, and I don't claim to have a good understanding of the intellectual property issues currently at the heart of Tekmira's valuation. What I do see is that the company has lost more than half their market cap since they began trading on the Nasdaq last November, and the current 29M cap seems better suited to scams and companies on the verge of bankruptcy. But no matter whose side you take in the controversy between Tekmira and Alnylam, it seems that Tekmira is being undervalued considering the weight of their contribution to the field thus far. They also have three proprietary RNAi compounds in or on the verge of clinical development for diverse indications. Cash was 12M as of the end of 2010 and their quarterly burn rate is unclear, which may become an issue. A pervasive negative attitude about RNAi in recent months may also be dragging down the share price. Portefeuille obviously believes in this stub strongly, and I think this one may be more FOLD than PARD.

Results 1 - 19 of 19

Featured Broker Partners


Advertisement